Reading File
analyse_media
analyse_media
Finding Sources
Searching PubMed
"Pseudomonas aeruginosa" AND "urinary tract infection" AND "extensively drug resistant"
Searching the Web
pan-resistant Pseudomonas aeruginosa UTI treatment options meropenem intermediate 2026
Finding Sources
Searching PubMed
"Pseudomonas aeruginosa" AND (cefiderocol OR "imipenem-relebactam") AND "difficult-to-treat"
Reading File
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC9952410
I now have comprehensive information to provide a thorough analysis. Here is the full breakdown:
Urine Culture & Sensitivity Report Analysis
Patient: Mr. Champalal Purohit | 51-year-old Male | Apollo Diagnostics, Hubli
Collected: 12 Jul 2026 | Reported: 15 Jul 2026
What the Report Shows
Culture Result
| Parameter | Finding |
|---|---|
| Organism | Pseudomonas aeruginosa |
| Colony Count | 100,000 CFU/mL |
| Significance | Definitive UTI (≥10^5 CFU/mL = significant growth) |
Antibiotic Susceptibility
| Antibiotic | MIC (µg/mL) | Result |
|---|---|---|
| Meropenem | 4 | INTERMEDIATE |
| Netilmicin | ≥32 | RESISTANT |
| Ceftolozane/Tazobactam | ≥32 | RESISTANT |
| Ceftazidime/Avibactam | ≥16 | RESISTANT |
| Levofloxacin | ≥8 | RESISTANT |
| Polymyxin B | ≥16 | RESISTANT |
| Cefepime | ≥32 | RESISTANT |
| Tobramycin | ≥16 | RESISTANT |
| Colistin | ≥16 | RESISTANT |
Critical Finding: Difficult-to-Treat Resistant (DTR) P. aeruginosa
This is an extremely concerning susceptibility profile. The IDSA defines DTR (Difficult-to-Treat Resistant) P. aeruginosa as non-susceptibility to all first-line agents: ceftazidime, cefepime, piperacillin-tazobactam, meropenem/imipenem, ciprofloxacin, levofloxacin, and aztreonam. This isolate meets that definition and goes further - it is also resistant to the "last-resort" agents Polymyxin B and Colistin, and to the newer beta-lactam/inhibitor combinations Ceftolozane/Tazobactam and Ceftazidime/Avibactam.
The only agent showing any activity is Meropenem, classified as Intermediate (MIC = 4 µg/mL; breakpoints: Sensitive ≤2, Intermediate = 4, Resistant ≥8).
What "Intermediate" Meropenem Means
An intermediate result does not mean the drug will fail. For UTIs specifically, meropenem achieves very high urinary concentrations, which can overcome intermediate MICs. According to the IDSA guidance on DTR-PA, this is actually a potentially exploitable window. However, standard dosing must be optimised to maximise pharmacodynamic target attainment.
Treatment Options - What Can Be Done
Priority 1: Optimised Meropenem (Best available option)
Since meropenem MIC = 4 (at the intermediate threshold), high-dose extended-infusion meropenem is the most practical option:
- Dose: 2g IV every 8 hours, infused over 3-4 hours (extended infusion)
- Extended infusion maximises the time that free drug concentrations remain above MIC (a time-dependent antibiotic)
- EAU 2026 Urological Infections Guidelines supports this for MDR Pseudomonas UTI
Priority 2: Cefiderocol (if available)
- Dose: 2g IV every 8 hours
- A novel siderophore cephalosporin - it hijacks iron transport channels to enter bacteria, bypassing most resistance mechanisms (stable against AmpC, ESBLs, KPC, OXA-48, and metallo-beta-lactamases)
- Specifically FDA-approved for complicated UTI including pyelonephritis
- The Washington Manual notes it covers Pseudomonas species resistant to all other beta-lactams
- IDSA recommends it as a preferred option for DTR-PA UTIs alongside newer beta-lactam/inhibitor combinations
- Given resistance to ceftolozane/tazobactam and ceftazidime/avibactam here, cefiderocol is likely the best novel agent to test
Priority 3: Imipenem/Cilastatin/Relebactam
- Dose: 1.25g IV every 6 hours
- Active against carbapenem-resistant P. aeruginosa via relebactam inhibiting AmpC and class A beta-lactamases
- Should be tested (it was not on this panel) - may show susceptibility
Why the Tested "Last-Resort" Agents Failed
- Colistin/Polymyxin B resistance (both MIC ≥16) is particularly alarming - this indicates likely modification of lipid A in the outer membrane (pmrB/phoP/arnBCADTEF mutations), removing the drug's binding target
- Ceftolozane/Tazobactam resistance (MIC ≥32) likely reflects AmpC hyperproduction or efflux pump upregulation (MexAB-OprM, MexXY-OprM)
- Ceftazidime/Avibactam resistance (MIC ≥16) in the setting of Colistin resistance suggests multiple simultaneous resistance mechanisms
Immediate Clinical Action Steps
- Urgent Infectious Disease (ID) consultation - This is a DTR organism and requires specialist management
- Request repeat susceptibility testing - Ask specifically for Cefiderocol and Imipenem/Cilastatin/Relebactam MICs, which are not on this panel
- Assess clinical severity - Is this a catheter-associated UTI, complicated UTI, or is there systemic involvement (fever, flank pain, bacteremia)?
- Blood cultures if systemic symptoms are present
- Imaging (renal ultrasound/CT) to rule out obstruction, abscess, or foreign body (catheter, stent) as source
- Remove any urinary catheter or foreign body if present - hardware is often the reservoir for resistant organisms and treatment will fail without source control
- If patient is symptomatic but not critically ill and no systemic infection: meropenem high-dose extended infusion while awaiting cefiderocol susceptibility
- Refer to a tertiary center with ID specialist access if not already in one
Key Context
P. aeruginosa is intrinsically resistant to many drug classes (it is a non-fermentative, Gram-negative bacillus). The report's own footnote confirms this: intrinsic resistance includes penicillins, 1st and 2nd generation cephalosporins, clindamycin, linezolid, vancomycin, erythromycin, azithromycin, and rifampin. The concern here is the acquired resistance to agents that should have worked (carbapenems, newer beta-lactam combinations, polymyxins).
Bottom line: This isolate is among the most resistant bacterial strains encountered clinically. It requires immediate specialist involvement, repeat susceptibility testing for cefiderocol and imipenem-relebactam, and likely IV treatment with high-dose extended-infusion meropenem as a bridge. Do not manage this empirically without an ID specialist.
Disclaimer: This analysis is for informational purposes only. Treatment decisions must be made by a qualified physician or infectious disease specialist who can assess the full clinical picture.
This is a shared conversation. Sign in to Orris to start your own chat.